Skip to main content
Log in

Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma

  • Original Articles
  • Melphalan Absorption
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2=10–12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the ‘PO fed’ and ‘PO fasting’ days: on the PO fed days the delay before absorption started was longer (1.1±0.5 h as against 0.3±0.1 h); peak plasma levels were one-third the value (65±15 ng/ml; 195±80 ng/ml) and occured at twice the time after administration (2.8±0.8 h; 1.3±0.3 h); and areas under the curve were smaller 10.8±4.7 min x μg/ml; 23.8±13.8 min x μg/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49±0.20) and on the PO fasting day (0.93±0.22), with P0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979a) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73

    Google Scholar 

  2. Alberts DS, Chang SY, Chen H-SG, Evans TL, Moon TE (1979b) Oral melphalan kinetics. Clin Pharmacol Ther 26:737

    Google Scholar 

  3. Bosanquet AG, Gilby ED (1982a) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355

    Google Scholar 

  4. Bosanquet AG, Gilby ED (1982b) Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography. J Chromatogr 232:345

    Google Scholar 

  5. Bosanquet AG, Bird MC, Price WJP, Gilby ED (1983a) An assessment of a short-term chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer 47:781

    Google Scholar 

  6. Bosanquet AG, Bird MC, Gilby ED (1983b) Short term tumor chemosensitivity assay for haematological cancers: Improved leucocyte identification and comparison of drug sensitivities in blood, marrow and lymph node: In: 13th International Congress of Chemotherapy, Vienna, 28th Aug, to 2nd Sept. 1983, Proceedings. Spitzy KH, Karrer K (eds). VH Egermann, Vienna, Part 224, p 130

    Google Scholar 

  7. Brox L, Birkett L, Belch A (1979) Pharmacology of intravenous melphalan in patients with multiple myeloma. Cancer Treat Rev [Suppl] 6:27

    Google Scholar 

  8. Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67:679

    Google Scholar 

  9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31

    CAS  PubMed  Google Scholar 

  10. McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milstead RAV, Prentice G, Smith IE, Spence D, Woods M (1979) Bone marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer 40:72

    Google Scholar 

  11. Metzler CM (1969) NONLIN: a computer program for parameter estimation in nonlinear situations. Upjohn Co., Kalamazoo (Technical Report 7292/69/7292/005)

    Google Scholar 

  12. Pallante SL, Fenselau C, Mennel RG, Brundrett RB, Appler M, Rosenshein NB, Colvin M (1980) Quantitation by gas chromatography-chemical ionisation mass spectrometry of phenylalanine mustard in plasma of patients. Cancer Res 40:2268

    Google Scholar 

  13. Pinkerton CR, Welshmam SG, Glasgow JFT, Bridges JM (1980) Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 2:944

    Google Scholar 

  14. Simpson HW, Stoney PJ (1977) A circadian variation of melphalan (l-phenylalanine nitrogen mustard) toxicity to murine bone marrow: relevance to cancer treatment protocols. Br J Haematol 35:459

    Google Scholar 

  15. Taha A-K, Ahmad RA, Gray H, Roberts CI, Rogers HJ (1982) Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 9:57

    Google Scholar 

  16. Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milstead RAV, Weinberg A (1978) Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14:507

    Google Scholar 

  17. Woodhouse KW, Hamilton P, Lennard A, Rawlins MD (1983) The pharmacolinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24:283

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosanquet, A.G., Gilby, E.D. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother. Pharmacol. 12, 183–186 (1984). https://doi.org/10.1007/BF00256542

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00256542

Keywords

Navigation